SLS
SELLAS Life Sciences Group, Inc · Healthcare · Biotechnology
$10.38
-14.71% today · -14.50% 1W
Oct 28 close or latest
After hours $10.38 0.00% ·
Meta Analyst score Buy 9.6/10 (+0.93 raw)
Every firm's latest rating in the past year, each weighted by its age (a 3-month-old call counts half as much as today's), blended with the consensus of 2 analysts (+1.50, counted like 1.5 fresh ratings), and pulled toward the typical S&P 500 score (+0.64) as if that were 3 more fresh ratings, so a score from few or old calls says less. 1 firm, 0 with a call in the past 3 months.
| Firm | Latest rating | Date | Weight |
|---|---|---|---|
| Maxim Group | Buy | Mar 12, 2026 | 4% |
Buy is what the ratings average to, +0.93 on a scale from −2 (strong sell) to +2 (strong buy). 9.6/10 means better than 96% of S&P 500 stocks (503 scored, Oct 25, 2026): analysts rarely say sell, so most stocks land between +0.4 and +0.8, and the 0–10 shows where this one sits among them.
Mean target
$32.50
+213.1% upside
Median target
$32.50
+213.1% upside
Target range
30.00–35.00
low to high
Analysts
2
as of Oct 28
Price vs. targets
Low $30
Mean $32
High $35
Now $10.38
Consensus
Strong buy 1Buy 1Hold 0Sell 0Strong sell 0
Rating and target changes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | Raised target | Buy | $7.00 → $10.00 |
Source: Yahoo Finance analyst data, collected daily.